Transformed to myelofibrosis is a risk factor for pulmonary hypertension in Philadelphia chromosome-negative myeloproliferative neoplasms

被引：0
作者：
Dina Suolitiken [1 ]
Xue Han [1 ]
Cuicui Feng [1 ]
Yini Wang [1 ]
机构：
[1] Department of Hematology, Capital Medical University Affiliated Beijing Anzhen Hospital, Beijing
来源：
Annals of Hematology | 2025年 / 104卷 / 4期
关键词：
Hypertension; Myelofibrosis; Myeloproliferative; Neoplasms; Pulmonary;
D O I：
10.1007/s00277-025-06334-w
中图分类号：
学科分类号：
摘要：
Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-MPNs) are a group of malignant clonal disorders originating from bone marrow hematopoietic stem cells, and pulmonary hypertension (PH) is a serious progressive disease often coexisting with Ph-MPNs, with a prevalence ranging from 5 to 50%. The aim of this study was to analyze the prevalence, clinical characteristics, and associated risk factors of PH in 130 patients with Ph-MPNs, to investigate the impact of PH on patients’ prognosis, and to provide a reference for the clinical identification of adverse prognostic factors and early prevention and treatment of PH. One hundred and thirty patients with Ph-MPNs treated at Beijing Anzhen Hospital from January 1, 2020 to December 31, 2024 were included in the study. PH risk was assessed by echocardiography (ECHO), and tricuspid regurgitation velocity (TRV) > 2.8 m/s was used as the criterion for high risk of PH. General information, hematological indices, biochemical indices, gene mutations and echocardiographic data of the patients were collected and statistically analyzed. The overall prevalence of PH among the 130 patients with Ph-MPNs was 15.4%. patients with PMF had the highest prevalence of PH (72.3%), which was significantly higher than that of patients with PV (9.9%) and ET (10.4%) (P < 0.05). patients in the PH high-risk group were older, had lower hemoglobin levels, and had a higher prevalence of splenomegaly and secondary myelofibrosis. the PH high-risk group Patients had a significantly higher mortality rate than the normal risk group (20% vs. 1.81%, P = 0.0004). Multifactorial Cox regression analysis showed that advanced age (HR = 1.029, P = 0.0332) and high risk of PH (HR = 1.034, P = 0.0432) were independent risk factors for patient survival.Logistic regression analysis showed that decreased hemoglobin (OR = 0.9657, P = 0.0062), splenomegaly (OR = 5.105, P = 0.0413) and secondary myelofibrosis (OR = 7.959, P = 0.0321) were independent risk factors for high risk of PH. This study revealed the prevalence of PH, risk factors, and their prognostic implications in patients with Ph-MPNs. It is suggested that regular monitoring of changes in relevant risk factors and vigilance and prevention of PH during the treatment of patients with Ph-MPNs are clinically important to improve the prognosis of patients. © The Author(s) 2025.
引用
收藏
页码：2279 / 2285
页数：6
相关论文
共 18 条
  • [1] Khoury J.D., Et al., The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms, Leukemia, 36, 7, pp. 1703-1719, (2022)
  • [2] Mocumbi A., Et al., Pulmonary hypertension, Nat Rev Dis Primers, 10, 1, (2024)
  • [3] Jindamai Y., Et al., Prevalence and risk factors of high echocardiographic probability of pulmonary hypertension in myeloproliferative neoplasms patients, Int J Hematol, 112, 5, pp. 631-639, (2020)
  • [4] Lee M., Et al., Pulmonary hypertension in patients with Philadelphia-negative myeloproliferative neoplasms: a single-center retrospective analysis of 225 patients, Blood Res, 55, 2, pp. 77-84, (2020)
  • [5] Kim J., Et al., Incremental utility of right ventricular dysfunction in patients with myeloproliferative Neoplasm–Associated pulmonary hypertension, J Am Soc Echocardiogr, 32, 12, pp. 1574-1585, (2019)
  • [6] Humbert M., Et al., 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension, Eur Heart J, 43, 38, pp. 3618-3731, (2022)
  • [7] Venton G., Et al., Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients, Eur J Intern Med, 68, pp. 71-75, (2019)
  • [8] Brabrand M., Et al., Frequency and etiology of pulmonary hypertension in patients with myeloproliferative neoplasms, Eur J Haematol, 102, 3, pp. 227-234, (2019)
  • [9] Boddu P., Et al., Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms, Ann Hematol, 97, 1, pp. 109-121, (2018)
  • [10] Greenfield G., McMullin M.F., Mills K., Molecular pathogenesis of the myeloproliferative neoplasms, J Hematol Oncol, 14, 1, (2021)
12